This is a prospective, single-arm First-in-Human study to demonstrate the safety and effectiveness of the CardioFocus OptiShot Pulsed Field Ablation System for catheter ablation of atrial fibrillation (AF). Patients with symptomatic paroxysmal (short-duration) AF who have not had a previous catheter ablation for AF will be considered for the study. Patients will be followed for one year after the initial ablation procedure.
Recurrent symptomatic PAF with at least one documented episode
Failure or intolerance of at least one AAD
Age 18-75 years
Patient is indicated for an ablation procedure according to society guidelines or study site practice
overall good health as established by multiple criteria